1. Brief report: Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
- Author
-
Rothe, Achim, Sasse, Stephanie, Goergen, Helen, Eichenauer, Dennis A., Lohri, Andreas, Jäger, Ulrich, Bangard, Christopher, Boll, Boris, von Bergwelt Baildon, Michael, Theurich, Sebastian, Borchmann, Peter, and Engert, Andreas
- Subjects
- *
HEMATOLOGIC malignancies , *ANTINEOPLASTIC agents , *CANCER relapse , *HODGKIN'S disease , *DRUG efficacy - Abstract
The CD30-targeting Ab-drug conjugate brentuximab vedotin (SGN-35) was re-cently approved for the treatment of re-lapsed Hodgkin lymphoma and anaplas-tic large-cell lymphoma by the Food and Drug Administration. In the present study, we report the experience of the German Hodgkin Study Group with brentuximab vedotin as single agent In 45 patients with refractory or relapsed CD30+ Hodgkin lymphoma who were treated either in a named patient program (n = 34) or in the context of a safety study associated with the registration program of this drug. In these very heavily pretreated patients, an objective response rate of 60%, Including 22% complete remissions, could be docu-mented. The median duration of response was 8 months. This retrospective analy-sis supports the previously reported ex-cellent therapeutic efficacy of brentux-imab vedotin in heavily pretreated CD30+ malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF